Kuros Biosciences Ltd. — Earnings Release 2009

Oct 22, 2009

News Details

Corporate | 22 October 2009 07:00

Cytos Biotechnology AG Third Quarter Report 2009

Cytos Biotechnology AG / Quarter Results

22.10.2009

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Cytos Biotechnology Ltd Third Quarter Report 2009 as of September 30, 2009

Summary of important events in Q3 2009

• CYT003-QbG10 monotherapy for the treatment of allergic
  rhinoconjunctivitis was safe and efficacious in phase IIb study

• Subsequent event:

  Interim analysis of an ongoing phase II study with nicotine vaccine
  shows primary endpoint not achieved

• Upcoming events:

  Presentation of Cytos Biotechnology at the Third International
  Conference on Modern Vaccines Adjuvants & Delivery Systems, October
  28-30, 2009 in Vienna, Austria

  Presentation of Cytos Biotechnology at the World Influenza Congress
  Europe 2009, December 7-9, 2009 in Brussel, Belgium

• Financial summary

in CHF million YTD* 09 YTD* 08 Q3 09 Q3 08
Revenue 8.4 5.9 1.8 0.4
Net operating costs (29.6) (30.8) (7.2) (10.3)
Net loss (23.6) (26.6) (5.6) (10.9)
09/30/09 12/31/08
Cash, cash equivalents, 71.4 98.0
financial assets
and trade receivables
Full-time employees (number) 86 132
* YTD = Jan 1 - Sept 30

The complete Third Quarter Report can be downloaded on Cytos
Biotechnology's website under the following link:

http://www.cytos.com/userfiles/file/Cytos_Q3_2009_E.pdf

Jakob Schlapbach, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 46 46
Fax: +41 44 733 47 02
e-Mail: jakob.schlapbach@cytos.com
Website: www.cytos.com

22.10.2009 Financial News transmitted by DGAP

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
WKN: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open Market in
Frankfurt; Foreign Exchange(s) SWX

End of News DGAP News-Service

---